Medicare as share of market, 2016
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

 
View only
 
 
ABCDEFG
1
Table 1: Medicare 2016 outlays as reported in CMS Medicare Dashboard, compared to US and global sales*
2
* Note: The Medicare Outlays reported in the CMS Medicare dashboard do not include rebates to manufactures, and thus overstate the net revenue to companies from Medicare sales, sometimes quite a bit, such as for Harvoni.
3
DrugCompany or CompaniesIndication2016 global salesUS as share of global salesMedicare dashboard as percent of globalMedicare dashboard as share of US sales
4
Xolair (omalizumab)
Genentech/Roche
Asthma and chronic idiopathic urticaria
1,498CHF100%27%27%
5
Perjeta (pertuzumab)GenentechCancer: BreastCHF1,84649%11%23%
6
Herceptin (trastuzumab)RocheCancer: BreastCHF6,78237%10%27%
7
Kadcyla (ado-trastuzumab emtansine)
RocheCancer: Breast831CHF38%14%37%
8
Ibrance (palbociclib)PfizerCancer: Breast$2,13597%47%48%
9
Afinitor (everolimus)Novartis
Cancer: Breast/Kidney/Pancreatic; Advanced GI/Lung NET; Renal Angiomyolipoma With Tuberous Sclerosis Complex; SEGA With Tuberous Sclerosis Complex
$1,51651%23%45%
10
Nexavar (sorafenib)
Bayer Healthcare
Cancer: Hepatocellular carcinoma (HCC); renal cell carcinoma (RCC); thyroid carcinoma (DTC)
€87036%23%65%
11
Inlyta (axitinib)
P.F. Prism C.V./Pfizer
Cancer: Kidney $40140%18%45%
12
Sutent (sunitinib)Pfizer
Cancer: Kidney; Gastrointestinal Stromal Tumor; Advanced Pancreatic NET
$1,09536%17%47%
13
Tasigna (nilotinib)NovartisCancer: Leukemia$1,73942%18%43%
14
Gleevec/Glivec (imatinib)NovartisCancer: Leukemia$3,32337%23%63%
15
Yervoy (ipilimumab)
Bristol-Myers Squibb (BMS)
Cancer: Melanoma$1,05376%22%30%
16
Zelboraf (vemurafenib)
Hoffman-La Roche
Cancer: Melanoma213CHF22%9%40%
17
Keytruda (pembrolizumabMerck
Cancer: Melanoma, NSCLC, HNSCC, cHL
$1,40256%0%1%
18
Revlimid (lenalidomide)Celgene
Cancer: Multiple myeloma
$6,97463%38%60%
19
Rituxan (rituximab)
Genentech (Roche)/Biogen IDEC
Cancer: non-Hodgkin’s lymphoma; chronic lymphocytic leukemia
7,300CHF54%24%45%
20
Xalkori (crizotinib)Pfizer
Cancer: Non-Small Cell Lung Cancer
$56145%17%39%
21
Tagrisso (osimertinib)AstraZeneca
Cancer: Non-Small Cell Lung Cancer
$42360%27%45%
22
Zytiga (abiraterone acetate)Janssen Biotech
Cancer: Prostate, testicular
$2,26048%36%76%
23
Remicade (infliximab)Janssen
Crohn's disease; pediatric Crohn's disease; ulcerative colitis; rheumatoid arthritis, psoriatic arthritis; Ankylosing spondylitis; plaque psoriasis
$6,96670%20%29%
24
Orkambi (ivacaftor; lumacaftor)
Vertex Pharmaceuticals
Cystic fibrosis$98092%8%9%
25
Humalog (insulin lispro recombinant)
Eli LillyDiabetes$2,76961%23%38%
26
Tresiba (insulin degludec)Novo NordiskDiabetes4,056 kr.55%24%44%
27
Invokana (canagliflozin)Janssen PharmsDiabetes$1,40790%43%48%
28
Fabrazyme (agalsidase beta)GenzymeFabry Disease€674.051%10%20%
29
Sovaldi (sofosbuvir)GileadHCV$4,00147%23%49%
30
Harvoni (ledipasvir; sofosbuvir)
GileadHCV$9,08154%48%89%
31
Complera/Eviplera (emtricitabine; rilviprine hydrochloride; tenofovir disoproxil fumarate)
GileadHIV$1,45756%12%21%
32
Truvada (emtricitabine/tenofovir)
GileadHIV$3,56667%18%27%
33
Atripla (efavirenz/emtricitabine/tenofovir)
GileadHIV$2,60573%20%28%
34
Cymbalta (duloxetine hydrochloride)
Lilly
Major Depressive Disorder
$93129%3%11%
35
Gilenya (fingolimod)NovartisMultiple Sclerosis$2,77661%16%26%
36
Tecfidera (dimethyl fumarate)Biogen IDECMultiple Sclerosis$3,96880%23%29%
37
Aubagio (teriflunomide)
Sanofi Aventis US
Multiple Sclerosis€1,29570%33%47%
38
Soliris (eculizumab paroxysmal nocturnal hemoglobinuria)
AlexionPNH; aHUS$2,84337%10%27%
39
Lumizyme (alglucosidase alfa)
Sanofi Genzyme
Pompe disease€72533%10%30%
40
Enbrel (etanercept)Amgen
Rheumatoid Arthritics; Plaque Psoriasis; Psoriaric Arthritics; Ankylosing Spondylitisl Juvenile Idiopathic Arthritis
$5,96596%26%27%
41
Humira (adalimumab)Abbvie
Rheumatoid arthritis (initial indication, now many more)
$16,07865%14%21%
Loading...
 
 
 
Summary: Medicare Share, 2016
Medicare Share, detials, 2016
Exchange rates
todo, Medicare
Review
 
 
Main menu